@article{7cf747d6e7d1487bac6570129c08ccb6,
title = "Identification of patient-specific CD4+ and CD8+ T cell neoantigens through HLA-unbiased genetic screens",
abstract = "Cancer neoantigens that arise from tumor mutations are drivers of tumor-specific T cell responses, but identification of T cell-recognized neoantigens in individual patients is challenging. Previous methods have restricted antigen discovery to selected HLA alleles, thereby limiting the breadth of neoantigen repertoires that can be uncovered. Here, we develop a genetic neoantigen screening system that allows sensitive identification of CD4+ and CD8+ T cell-recognized neoantigens across patients{\textquoteright} complete HLA genotypes.",
author = "Cattaneo, \{Chiara M.\} and Thomas Battaglia and Jos Urbanus and Ziva Moravec and Rhianne Voogd and \{de Groot\}, Rosa and Hartemink, \{Koen J.\} and Haanen, \{John B. A. G.\} and Voest, \{Emile E.\} and Schumacher, \{Ton N.\} and Wouter Scheper",
note = "Funding Information: We would like to thank M. Slagter and L. Wessels for bioinformatic and statistical support, K. Dijkstra for support with single-cell TCR sequencing, A. van de Leun for support with isolation of neoantigen-specific TCRs, M. Wolkers for kindly sharing patient material, K. Bresser and D. Vredevoogd for helpful discussions on library design, the NKI-AVL Flow Cytometry Facility for flow cytometric support, the NKI-AVL Core Facility Molecular Pathology and Biobanking for supplying NKI-AVL Biobank material and laboratory support and the NKI-AVL Genomics Core Facility for support with next-generation sequencing. This work was supported by the Dutch Cancer Society Young Investigator Grant (grant No. 2020-1/12977) (to W.S.), ZonMw Translational Research Program 2 (grant No. 446002001) (to W.S. and J.B.A.G.H.), the Queen Wilhelmina Cancer Research Award and ERC AdG SENSIT (grant agreement No. 742259) (to T.N.S.), the NWO Gravitation program (NWO 2012-2022) (to E.E.V.) and Oncode Institute (to T.N.S. and E.E.V.). Figure 1a was created with BioRender.com. Funding Information: T.N.S. is advisor for Allogene Therapeutics, Celsius, Merus, Neogene Therapeutics and Scenic Biotech; is a recipient of research support from Merck KgaA; is a stockholder in Allogene Therapeutics, Cell Control, Celsius, Merus, Neogene Therapeutics and Scenic Biotech and is venture partner at Third Rock Ventures, all outside of the current work. J.B.A.G.H. is advisor for BioNTech, Neogene Therapeutics, Scenic Biotech and T-Knife; is a recipient of research grant support from BioNTech; is a stock option holder in Neogene Therapeutics, all outside of the current work. All other authors declare no competing interests. Funding Information: We would like to thank M. Slagter and L. Wessels for bioinformatic and statistical support, K. Dijkstra for support with single-cell TCR sequencing, A. van de Leun for support with isolation of neoantigen-specific TCRs, M. Wolkers for kindly sharing patient material, K. Bresser and D. Vredevoogd for helpful discussions on library design, the NKI-AVL Flow Cytometry Facility for flow cytometric support, the NKI-AVL Core Facility Molecular Pathology and Biobanking for supplying NKI-AVL Biobank material and laboratory support and the NKI-AVL Genomics Core Facility for support with next-generation sequencing. This work was supported by the Dutch Cancer Society Young Investigator Grant (grant No. 2020-1/12977) (to W.S.), ZonMw Translational Research Program 2 (grant No. 446002001) (to W.S. and J.B.A.G.H.), the Queen Wilhelmina Cancer Research Award and ERC AdG SENSIT (grant agreement No. 742259) (to T.N.S.), the NWO Gravitation program (NWO 2012-2022) (to E.E.V.) and Oncode Institute (to T.N.S. and E.E.V.). Figure was created with BioRender.com . Publisher Copyright: {\textcopyright} 2023, The Author(s).",
year = "2023",
month = jun,
doi = "10.1038/s41587-022-01547-0",
language = "English",
volume = "41",
pages = "783--787",
journal = "Nature biotechnology",
issn = "1087-0156",
publisher = "Nature Publishing Group",
number = "6",
}
SDG 3 Good Health and Well-being